Dr Rishabh Jain· @DrRishabhOnco · X·· 2 天前评分90
正文 · 机器翻译
🚨 #ESMO26 | SANO 试验（LBA78）
新辅助CRT后完全缓解的食管癌患者能否免于手术？
5年结局（n=309）：
🔹 OS：50% vs 54%（HR 1.17）
🔹 远处转移：46% vs 29%（p<0.01）
🔹 43%的患者免于无益的食管切除术。
🎯 结论：主动监测可实现器官保留，且OS差异无统计学意义，但远处转移率较高，引发担忧。
对于经过严格筛选的患者，监测能否成为标准治疗选择？
@ESMO_open @my_esmo @ASCO @oncoalert
#SANO #EsophagealCancer
1002 浏览 · 8 赞 · 3 转发 · 0 回复
会议摘要
LBA78按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: Long-term results of a cluster-randomised controlled trial (SANO)
https://esmocongress.esmo.org🚨 ESMO 2026 | TOP 10 GI CANCER TRIALS TO WATCH! From CLDN18.2 ADCs and PD-1/VEGF bispecifics to chemotherapy-free strategies, major GI oncology data are coming at #ESMO26! 🔥 My Top 10 Trials 🔴 GASTRIC / GEJ CANCER CLARITY-Gastric 01 (LBA7) | CLDN18.2 ADC vs investigator’s choice G-HOPE-001 (LBA77) | Novel CLDN18.2 ADC HERIZON-GEA-01 (LBA79) | Zanidatamab + chemotherapy ± tislelizumab GERCOR-GONO DEWI | Dostarlimab and nonoperative management in dMMR disease LOMAC (LBA81) | 4 vs 6 months of adjuvant CAPOX KC-WISE (LBA80) | Anbenitamab + chemotherapy RAMIRIS | FOLFIRI + ramucirumab vs paclitaxel + ramucirumab FORTITUDE-101/102 | FGFR2-targeted therapy and biomarker analysis 🟠 BILIARY TRACT CANCER HARMONi-GI1 (LBA8) | Ivonescimab + chemotherapy vs durvalumab + chemotherapy 🟣 ESOPHAGEAL / GEJ CANCER KEYNOTE-975 (2875O) | Pembrolizumab + definitive chemoradiotherapy ⭐ Two Presidential trials to watch closely: CLARITY-Gastric 01 and HARMONi-GI1. Which GI trial will have the greatest clinical impact? @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #GICancer #Oncology在 X 查看被引用的帖子
来源：Dr Rishabh Jain · x.com